愛美客(300896.SZ):上半年淨利預增60%-70% 持續提升產品競爭力和品牌影響力
格隆匯8月3日丨愛美客(300896.SZ)公佈2023年半年度業績預吿,報吿期歸屬於上市公司股東的淨利潤盈利9.35億元–9.95億元,比上年同期增長60%–70%;扣除非經常性損益後的淨利潤盈利9.08億元–9.68億元,比上年同期增長61%–71%。
報吿期內,公司依託已有的行業龍頭地位和品牌認可度,在營銷端和產品端持續發力,業績取得較大幅度增長。在營銷端,公司繼續堅持“直銷為主,經銷為輔”的營銷模式,提升與下游醫療美容機構合作的廣度和深度。在產品端,公司憑藉全方位且具差異化的產品矩陣,清晰的產品定位,持續提升產品競爭力和品牌影響力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.